Clinical Trials Logo

Brain Tumor, Recurrent clinical trials

View clinical trials related to Brain Tumor, Recurrent.

Filter by:

NCT ID: NCT00747253 Completed - Clinical trials for Glioblastoma Multiforme

Monteris AutoLITTâ„¢ FIM Safety Trial for Recurrent/Progressive Brain Tumors

Start date: August 2008
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).

NCT ID: NCT00575887 Completed - Glioblastoma Clinical Trials

Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.

NCT ID: NCT00179907 Completed - Clinical trials for Glioblastoma Multiforme

A Phase I/II Study of the Photon Radiosurgery System

Start date: May 2001
Phase: Phase 1/Phase 2
Study type: Interventional

The standard treatment for children with brain tumors is surgical removal of the tumor followed by radiation to the brain and chemotherapy (medicines) given to shrink any remaining tumor or to prevent tumor from growing back. There are very few treatment options available for children whose brain tumor grows back after receiving radiation treatment. There is a greater risk of complications and side effects when the brain is repeatedly treated with external radiation. The side effects of repeat radiation treatment are dependent on the amount of the brain that is radiated. Radiation given with PRS during surgery is focused to the specific area of the brain where the tumor is located. Therefore, the area of the brain affected by the radiation is smaller. It is hoped that this targeted radiation will lessen the side effects to the normal brain that is not affected by the tumor. It is also hoped that a lower occurrence of side effects will increase the quality of life of children with brain tumors. The optimal dose of targeted radiation is not known. Therefore, increasing doses will be given to treat different patients, starting with the lowest possible dose. The amount of radiation to be given will depend on whether or not your child received prior radiation therapy and where the tumor is located. The groups of patients will first be divided into 2 groups: Group A, who are those who received radiation as part of their prior treatment, and Group B, who are those who did not receive any radiation treatment. Each group will be then divided again into 2 groups depending on the location of the tumor. In each group, if the lowest dose is well-tolerated with only minimal side effects by 3 patients, then the next higher dose will be given to the next 3 patients. The purposes of this research are: - To evaluate the potential side effects of a single high dose of x-rays using the Photon Radiosurgery System (PRS) given to a small area of the brain. - To determine the maximum dose of targeted radiation that can be safely given to brain tumors with the fewest side effects. - To see how well this treatment works for children with recurrent brain tumors and newly-diagnosed glioblastoma multiforme.

NCT ID: NCT00141765 Completed - Wilms Tumor Clinical Trials

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

Start date: January 1997
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.